Skip to main content
Clinical Trials/NCT02982668
NCT02982668
Terminated
Not Applicable

A Multi-center Randomised Controlled Trial to Explore the Ideal Initial Enteral Feeding Strategies in Patients With Severe Stroke at Acute Stage

Xijing Hospital4 sites in 1 country306 target enrollmentJanuary 2017

Overview

Phase
Not Applicable
Intervention
Initial enteral feeding
Conditions
Severe Stroke
Sponsor
Xijing Hospital
Enrollment
306
Locations
4
Primary Endpoint
Rate of patients with death or major disability (modified Rankin scale score ≥3)
Status
Terminated
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this academic lead study is to explore the ideal nutritional support strategy for patient with acute severe stroke.

Detailed Description

Of high mortality and morbidity, severe stroke is associated with devastating damages in neurologic, respiratory, circulatory and many other systems. The outcomes of patients with severe stroke depend largely on medical strategies on acute stage, especially on nutritional support management. Unfortunately, clinical evidence are sparse and the ideal initial feeding strategy remains disputable. The IF-STROKE study aims to provide reliable data on the effects of modified full enteral feeding (target recruitment 200) and permissive underfeeding in patients with acute severe stroke (target recruitment 200) compared to full enteral feeding (target recruitment 200). Patients presenting with acute (\<72h) severe stroke (GCS ≦ 12 or NIHSS ≧ 11) and dysphagia (defined by Water Swallowing Test) will be randomly assigned to full enteral feeding, modified full enteral feeding, or permissive underfeeding treatment for 7 days.

Registry
clinicaltrials.gov
Start Date
January 2017
End Date
December 2020
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Xijing Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Severe stroke occurred in 7 days.
  • GCS ≤12 or NIHSS≥
  • Any cases of profiles #3 through 5 in Water Swallowing Test or with disorder of consciousness.
  • Plan to receive enteral feeding for at least 7 days.
  • Informed consent.

Exclusion Criteria

  • Gastrointestinal diseases before stroke, such as gastrointestinal resection, malabsorption,and irritable bowel syndrome.
  • Brain death.
  • Complicated with the disease which only have life expectancy \< 6 months in over 50% patients.
  • After cardiac arrest.
  • Received parenteral nutrition support.
  • Pregnant woman.
  • Concurrent severe hepatic or renal dysfunction。
  • Unstable hemodynamics.

Arms & Interventions

Full enteral feeding

The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.

Intervention: Initial enteral feeding

Modified full enteral feeding

Consistent with full enteral feeding plan, preventively add metoclopramide or mosapride everyday to improve gastrointestinal (GI) motility.

Intervention: Initial enteral feeding

Modified full enteral feeding

Consistent with full enteral feeding plan, preventively add metoclopramide or mosapride everyday to improve gastrointestinal (GI) motility.

Intervention: metoclopramide or mosapride

Permissive underfeeding

The caloric goal of the first day is one-third of caloric requirements, the second day is 40-60% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.

Intervention: Initial enteral feeding

Outcomes

Primary Outcomes

Rate of patients with death or major disability (modified Rankin scale score ≥3)

Time Frame: 3 months after enrollment

modified Rankin scale score, with score ranging from 0 (normal) to 6 (death), was used to evaluate the functional outcomes after stroke.

Secondary Outcomes

  • Mortality (rate of patients with death)(3 months after enrollment)
  • The scores of National Institute of Health stroke scale(7 days after enrollment)
  • Glasgow Coma Scale(7 days after enrollment)
  • modified Rankin scale(3 months after enrollment)
  • Barthel index(3 months after enrollment)
  • The incidence of treatment intolerance(7 days after enrollment)
  • The incidence of serious adverse events(3 months after enrollment)
  • The incidence of adverse events That are related to treatment(3 months after enrollment)

Study Sites (4)

Loading locations...

Similar Trials